Mirador Capital Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Mirador Capital Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.2M	Buy	1,095,740 +15,452	+1%	+$111K	1.89%	16
2026 Q2	$4.49M	Buy	1,080,288 +7,052	+0.7%	+$26.8K	0.55%	45
2026 Q1	$3.77M	Buy	1,073,236 +38,692	+4%	+$124K	0.53%	45
2025 Q4	$2.82M	Buy	1,034,544 +519,519	+101%	+$1.2M	0.39%	58
2025 Q3	$1.12M	Buy	+515,025	New	+$1.22M	0.16%	95
2022 Q4	–	Sell	-63,479	Closed	-$608K	–	195
2022 Q3	$608K	Sell	63,479 -1,211	-2%	-$14K	0.15%	93
2022 Q2	$714K	Buy	64,690 +21,585	+50%	+$283K	0.17%	93
2022 Q1	$718K	Buy	43,105 +3,039	+8%	+$47K	0.15%	103
2021 Q4	$765K	Buy	40,066 +14,772	+58%	+$325K	0.16%	104
2021 Q3	$624K	Buy	25,294 +1,036	+4%	+$24.4K	0.14%	120
2021 Q2	$631K	Buy	+24,258	New	+$631K	0.14%	119

Other funds holding IOVA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

SMAM

Sugar Maple Asset Management Sister Bay, Wisconsin $175M AUM 16.33% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CWM

Centurion Wealth Management Mclean, Virginia $415M AUM 17.23% 1-Year Est. Return

HCG

Haven Capital Group Westlake Village, California $131M AUM 23.95% 1-Year Est. Return

AWM

Able Wealth Management Toms River, New Jersey $455M AUM 13.63% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Mirador Capital Partners's IOVA Position: Q3 2026 in Review

Mirador Capital Partners increased its Iovance Biotherapeutics (IOVA) stake by 1.4% in Q3 2026, buying an estimated $111K and bringing the position to 1,095,740 shares worth $16.2M. The position accounts for 1.89% of the portfolio, ranked #16.

Mirador Capital Partners first reported a position in IOVA in Q2 2021 and has held it in 11 quarters since. 13 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

Mirador Capital Partners held 1,095,740 shares of Iovance Biotherapeutics worth $16.2M as of Q3 2026.
Mirador Capital Partners bought 15,452 Iovance Biotherapeutics shares in Q3 2026, an estimated $111K.
Iovance Biotherapeutics made up 1.89% of Mirador Capital Partners's portfolio in Q3 2026, its #16 holding.
Mirador Capital Partners first reported a position in Iovance Biotherapeutics in Q2 2021 and has held it in 11 quarters since.
13 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Mirador Capital Partners's 13F filing for Q3 2026, filed 9 Oct 2026.